The company said it filed on May 3, 2024 a prospectus supplement (the Resale Prospectus Supplement) to its previously filed automatic shelf registration statement on Form S-3 (File No. 333-279011).

1. 01

   The company said it filed on May 3, 2024 a prospectus supplement (the Resale Prospectus Supplement) to its previously filed automatic shelf registration statement on Form S-3 (File No. 333-279011).

2. 02

   The company said the supplement registers the resale of up to 85,608,414 shares of common stock, par value $0.01 per share, which the selling stockholder named in the supplement may use to resell those shares.

3. 03

   The company said it is filing this Form 8-K to file the legal opinion on the validity of the shares in connection with the resale prospectus supplement.

4. 04

   The company said it filed the opinion of Wachtell, Lipton, Rosen & Katz (Exhibit 5.1) and the firm's consent (Exhibit 23.1, included in Exhibit 5.1) as attachments.

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.